The eŠects of losartan potassium, an angiotensin AT 1 receptor blocker on immobility in forced swim test have been studied. EŠect of losartan potassium, nortriptyline HCl, ‰uoxetine HCl and reserpine per se and in combination on forced swimming-induced immobility in mice have also been studied. In mice, losartan potassium elicits biphasic responses i.e. positive responses at lower doses (0.1, 1.0 and 5 mg/kg, i.p.) in the forced swim test, a test of potential antidepressant activity and vice versa at higher dose (20 and 100 mg/kg, i.p.). In chronic studies, enhancement in immobility was observed for losartan potassium (3 and 30 mg/kg, p.o., 21 days). In acute combination studies, losartan potassium (1 and 5 mg/kg) signiˆcantly reversed the reserpine-induced immobility, but vice versa at 100 mg/kg. Losartan potassium (0.1 and 5 mg/kg) potentiate antidepressant activity of nortriptyline (30 mg/kg, i.p.) in mice, but vice versa at 100 mg/kg. Likewise, Losartan potassium (100 mg/kg), signiˆcantly reversed antidepressant activity of ‰uoxe-tine HCl, but at 0.1 and 5 mg/kg, failed to modify ‰uoxetine HCl induced immobility. The obtained biphasic eŠect of losartan potassium on immobility in mice might be due to inhibitory eŠect on AT 1 receptor at lower dose and pronounced eŠect on AT 2 receptor at higher dose (large concentrations of losartan potassium can displace Angiotensin II (Ang II) from its AT 1 receptor to AT 2 receptor.
INTRODUCTION
The presence of a separate renin angiotensin system (RAS) within the mammalian brain complete with the precursors and enzymes necessary for the formation and deactivation of the physiologically active forms of angiotensin (Ang) was supported in many investigations. 1, 2) The eŠector peptide of the RAS Ang II, binds at least to two G protein coupled receptor subtypes, referred to as the AT 1 and the AT 2 receptors. Ang II is known to stimulate catecholamine release 3) mediated by an AT 1 subtype 4) is located on presynaptic nerve terminals. In case of AT 1 receptor blockade, which is supposed to reduce catecholamine release leading to endogenous depression. Since deˆciency of aminergic transmission in the CNS might be causative of endogenous depression. 5, 6) But on the converse, losartan an AT 1 blocker elicits positive responses in the forced swim test, a test of potential antidepressant activity. 7) These controversial observations lead us to conduct studies on eŠects of losartan potassium on immobility in mice.
MATERIALS AND METHODS
Male albino mice (Swiss, 20 25 gm) used in these studies were allowed food and water ad libitum up to the time of experimentation. Prior to use, the mice were housed in polypropylene cages in groups of six to eight animals under natural light-dark cycle. Institutional Animal Ethics Committee has approved all studies reported here (protocol Number IAEC/RES/ 5, dated 21/04/2003).
Losartan potassium, ‰uoxetine HCl (Sun Pharma, India), nortriptyline HCl (Sigma, USA) were dissolved in normal saline and was given i.p. Reserpine (Loba Chemicals, India) was dissolved in a few drops of glacial acetic acid and the volume was makeup with normal saline. The drug solutions were prepared afresh at beginning of each experiment. In acute studies, all the drugs were administered by i.p. in a constant volume of 1 ml per 100 gm of body weight. In chronic studies, required dose of losartan potassium (3 & 30 mg/kg) was dissolved in per day consumption of drinking water (12 ml/100 gm of body weight) and made available for 21 days.
The behavioral despair test has been used as a test of depressive like behavior. 8) The animals were forced to swim individually in a glass cylinder (30 cm high, 22.5 cm in diameter) containing 15 cm water at room temperature. The animals were individually trained in 15 min sessions, using the apparatus described above one day prior to the experimentation. During ex- perimentation each animal was placed on the cylinder one at a time and left there for 6 min. The duration of immobility for each mouse was recorded. A mouse was judged to be immobile when it ceased struggling and remaining ‰oating motionless in the water making only movements necessary to keep its head above water.
Statistical Analysis
Results are presented as the mean±SEM. Experimental data in Table 1 , were analyzed by one way analysis of variance (ANOVA) followed by post hoc comparisons between drug treated at various time intervals and vehicle treated control groups using Dunnett's test. In Table 2 , experimental data were analyzed by one way analysis of variance (ANOVA) followed by Student's t-test. Statistical signiˆcance was set at p＜0.05.
RESULTS
EŠect of losartan potassium, nortriptyline HCl, ‰uoxetine HCl and reserpine per se and in combination studies on forced swimming-induced immobility in mice is shown in Tables 1 and 2 . As shown in Table  1 , in comparison to control, losartan potassium (0.1, 1 and 5 mg/kg, i.p.) signiˆcantly reduced immobility Table 2 , losartan potassium (1 and 5 mg/kg) signiˆcantly reversed the reserpine-induced immobility in mice, but enhanced in immobility at 100 mg/kg. Losartan potassium (0.1 and 5 mg/kg) potentiated antidepressant activity of nortriptyline (30 mg/kg, i.p.) in mice, but at 100 mg/kg, signiˆcantly reversed it. Likewise, Losartan potassium (100 mg/kg), signiˆcantly reversed antidepressant activity of ‰uoxe-tine HCl, but at 0.1 and 5 mg/kg, failed to modify ‰uoxetine HCl induced immobility.
DISCUSSION
It has been previously reported, the antidepressant drugs desipramine, ‰uoxetine and tranylcypromine are able to antagonize the eŠects of Ang in rats, both in vivo and in vitro. 9) Giardina and Ebert 10) (1989) showed that captopril elicits antidepressant like eŠects in an animal model and extend the previous work by showing that losartan has similar actions. 7) Based on these observations, it has been hypothesized that inhibition of Ang function is important in the treatment of endogenous depression. The results of present studies showed biphasic eŠects of losartan potassium on immobility in mice (i.e.) reduced immobility at lower dose (0.1, 1 and 5 mg/kg) enhanced immobility in higher dose (100 mg/kg, i.p.). The biphasic eŠect was further conˆrmed by interaction of losartan potassium with reserpine and antidepressant drugs nortriptyline and ‰uoxetine ( Table  2) . Nahmod et al found Ang II to cause 5HT release and accelerate its synthesis in biphasic manner, stimulating at high doses and inhibiting at lower doses. 11) Using the micro dialysis technique, it was demonstrated that stimulation of periventricular AT 1 receptors leads to release of noradrenaline in the paravetricular nucleus and the supraoptic nucleus. 12, 13) The research on the Ang receptor subtype characterization in the brain has been reviewed. 14) Both the AT 1 and AT 2 receptors have been localized in the brain RAS 15) together with their mRNAs. 16) In ro-dents AT 1A receptor has been found in brain areas involved in blood pressure and ‰uid homeostasis. The AT 1B receptor is present in glandular tissues, such as anterior pituitary, pineal, adrenal gland, and testes. 17) The AT 2 receptor is densely expressed in the lateral septum, in several thalamic nuclei, in sub thalamic nucleus, in locus cerules and in the inferior olive. 18) Activation of AT 2 receptor seems to induce eŠects opposite to that of AT 1 . 19) AT 2 stimulation inhibits drinking responses and vasopressin release following centrally administered Ang II, 20) promotes diŠerenti-ation and axonal regeneration, and inhibits proliferation of neuronal cells. 21) Thus the counteracting eŠects between AT 1 and AT 2 receptors suggest that a negative cross talk exist between the AT 1 and AT 2 receptors, 22) as is the case in catecholaminergic neurons. 23) Most of the central eŠects of Ang peptides, which are mediated by AT 1 receptor, are under control by AT 2 receptor. They are in accordance with earlierˆndings from in vitro experiments in endothelial cells where growth promoting eŠects mediated by AT 1 receptors were counteracted by growth inhibitory actions of AT 2 receptors. 24) Opposite eŠects of AT 1 and AT 2 receptors on the second messenger phosphatidylinositol have also been described by Gyurko et al. 25) AT 1 selective receptor antagonists are known to bind to AT 2 receptors with low a‹nity and vice versa. However, the selectivity is not absolute, and large concentrations of AT 1 selective receptor antagonists can displace Ang II from AT 1 receptors to the alternative site ( AT 2 receptors). 26) The obtained biphasic eŠect of losartan potassium on immobility in mice might be due to inhibitory eŠect on AT 1 receptor at lower dose and pronounced eŠect on AT 2 receptor at higher dose (large concentrations of losartan potassium can displace Ang II from its AT 1 receptor to AT 2 receptor). In chronic studies with losartan potassium even at lower dose (3 mg/kg, p.o.) potentiated immobility in mice, which might be due to continuous blockade of AT 1 receptor resulting in unopposed AT 2 receptor stimulation. It has also been previously reported that the treatment of Ang II for 4 h has a biphasic eŠect on Na ＋ transport in the primary cultured rabbit renal proximal tubule cells (PTCs); a Pico molar range of Ang II stimulates Na ＋ transport, whereas a micro molar range of Ang II inhibits it. 27) Antagonist 29) In these studies, treatment of cells with increasing concentrations of Ang II caused a dose-dependent inhibition of AT 1 and AT 2 binding sites and mRNAs. The maximal inhibitory eŠect was observed at 10 -7 M, but the IC 50 for AT 1 and AT 2 -binding sites and AT 1 mRNA (3±0.43±10 -9 M) were signiˆcantly higher than that for AT 2 mRNA (2.8±0.3×10 -10 M). However, the most striking diŠerences were observed in the time-course eŠects of Ang II. AT 1 -binding sites decreased very rapidly, and by 3 h, more than 50％ of the surface receptors disappeared. In contrast, the eŠects of Ang II on AT 2 -binding sites were not signiˆcant during theˆrst hours of treatment. Thereafter, the surface receptor declined with an apparent half-life of 14-16 h. Similarly, the eŠects on AT 2 mRNA were not signiˆcant during theˆrst 6 h of treatment, but then the levels dramatically decreased, with an apparent half-life of 2 h. 29) In higher doses of losartan potassium (20 and 100 mg/kg, i.p.) enhancement in immobility was observed even after 3 hs of losartan potassium treatment. The terminal half-life of losartan p.o. is 2.12 h and its active metabolite EXP 3174 (carboxylic acid derivative) about 6 to 9 h. 30) It is reported that the eŠect of i.p. administration of losartan (20 mmol/kg) on Ang II induced drinking was found to be reduced at 4, 12 and 24 h. EXP 3174 signiˆcantly reduced the Ang II induced water intake even at 0.25 h. Therefore, the ability of peripherally administered losartan in‰uencing central Ang mechanisms might be accounted for EXP 3174, which is about 20 times more potent than losartan to inhibit central AT 1 receptors and which apparently crosses the blood-brain barrier rather well. 31) 
